WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to control Hard-to-Treat blood cancer
Disease control Not yet recruitingThis study tests two drugs, mosunetuzumab and pirtobrutinib, given together to people with Waldenstrom macroglobulinemia (a rare blood cancer) that has returned or not responded to prior therapy. The goal is to find a safe dose and see how well the combination controls the diseas…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New triple-drug attack targets rare blood cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) in people with Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to see how well the treatment shrinks tumors and controls the disease. About 19 adults who have not yet been t…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called LY4152199 in adults with B-cell cancers (like certain lymphomas) that have come back or not responded to prior treatments. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to find the safes…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New combo pill attack on rare blood cancer shows promise
Disease control Not yet recruitingThis study tests a combination of two oral drugs, zanubrutinib and BGB-11417, in people with Waldenström macroglobulinemia (a rare blood cancer) who have already received at least one prior treatment. About 102 adults will take the drugs for up to 20 months to see if the combo ca…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC